Sotatercept, an activin signaling inhibitor, has been recently approved by the FDA for treating pulmonary arterial hypertension (PAH) (see our recent article about the FDA approval at this link), based on two pivotal clinical trials. The authors of the article titled “How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, published on the CHEST Journal on July 14, 2024, present a case-based discussion addressing common clinical decisions in pulmonary arterial hypertension treatment. Topics include diagnostic testing, first-line agent selection, therapy escalation, timing for sotatercept use, safety considerations, practical application, potential management adjustments, and future applications of sotatercept in other pulmonary hypertension groups.
This article is not open access. The abstract is available to the general public at this link
Citation
Preston IR, Lewis D, Gomberg-Maitland M. How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension. Chest. 2024 Jul 12:S0012-3692(24)04611-7. doi: 10.1016/j.chest.2024.06.3801. Epub ahead of print. PMID: 39004216.